Which antipsychotic medication is notably associated with agranulocytosis and not with extrapyramidal side effects?

Clozapine is an atypical antipsychotic that has a unique profile compared to other antipsychotics. One of its notable risks is agranulocytosis, which is a severe decrease in white blood cell count that can lead to increased susceptibility to infections. This risk necessitates regular monitoring of the patient's white blood cell counts, especially during the initial treatment phases, due to the potential life-threatening nature of this side effect.

In contrast to clozapine, other antipsychotic medications such as risperidone, quetiapine, and olanzapine are more commonly associated with extrapyramidal side effects (EPS), which include symptoms such as tremors, rigidity, and bradykinesia, akin to Parkinsonism. While these other medications can have a variety of side effects, they are generally considered to have a lower risk of agranulocytosis compared to clozapine.

Thus, identifying clozapine as the medication notably tied to agranulocytosis without the concern of extrapyramidal side effects illustrates its distinct safety profile and the importance of extensive blood monitoring during treatment.